MedTrace Logo

Cholesterol-Lowering Atherosclerosis Study (CLAS)

NCT00000599 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-12-13

No results posted yet for this study

Summary

To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride plus niacin would produce significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions as determined by angiography. Also, to determine possible correlations between lesion changes and plasma lipid and lipoprotein cholesterol levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and carotid arteries.

Conditions

  • Arterial Occlusive Diseases
  • Cardiovascular Diseases
  • Carotid Artery Diseases
  • Cerebral Arteriosclerosis
  • Cerebrovascular Disorders
  • Coronary Arteriosclerosis
  • Coronary Disease
  • Heart Diseases
  • Myocardial Ischemia
  • Atherosclerosis

Interventions

DRUG

colestipol

DRUG

niacin

BEHAVIORAL

diet, fat-restricted

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Stanley Azen · University of Southern California

  • David Blankenhorn · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
40 Years
Max Age
59 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1980-06-30
Completion
1994-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000599 on ClinicalTrials.gov